Co-Existing Prostate Cancer and Diabetes Mellitus: Implications for Patient Outcomes and Care

Karlin, Nina J.; Amin, Shailja; Verona, Patricia M; Kosiorek, Heidi E.; Cook, Curtiss B.

doi:10.4158/ep161702.or

Cited by 22 publications

(38 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most recently a case–control study showed no impact of PCa diagnosis on mean HbA1c or glucose. 19 However, over 70% of patients in this study underwent prostatectomy and therefore did not receive ADT.…”

Section: Discussionmentioning

confidence: 88%

Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study

et al. 2018

View full text Add to dashboard Cite

ObjectivesBoth prostate cancer (PCa) and type 2 diabetes mellitus (T2DM) are increasingly prevalent conditions, which frequently coexist in men. Here, we set out to specifically examine the impact of a PCa diagnosis and its treatment on T2DM treatment.SettingThis study uses observational data from Prostate Cancer database Sweden Traject.ParticipantsThe study was undertaken in a cohort of 16 778 men with T2DM, of whom 962 were diagnosed with PCa during mean follow-up of 2.5 years.Primary and secondary outcome measuresWe investigated the association between PCa diagnosis and escalation in T2DM treatment in this cohort. A treatment escalation was defined as a new or change in anti-T2DM prescription, as recorded in the prescribed drug register (ie, change from diet to metformin or sulphonylurea or insulin). We also investigated how PCa diagnosis was associated with two treatment escalations. Multivariate Cox proportional hazards regression with age as a time scale was used while adjusting for educational level and initial T2DM treatment.ResultsWe found no association between PCa diagnosis and risk of a single treatment escalation (HR 0.99, 95% CI 0.87 to 1.13). However, PCa diagnosis was associated with an increased risk of receiving two consecutive T2DM treatment escalations (HR 1.75, 95% CI 1.38 to 2.22). This increase was strongest for men on gonadotropin-releasing hormone (GnRH) agonists (HR 3.08, 95% CI 2.14 to 4.40). The corresponding HR for men with PCa not on hormonal treatment was 1.40 (95% CI 1.03 to 1.92) and for men with PCa on antiandrogens 0.91 (95% CI 0.29 to 2.82).ConclusionsMen with T2DM who are diagnosed with PCa, particularly those treated with GnRH agonists, were more likely to have two consecutive escalations in T2DM treatment. This suggests a need for closer monitoring of men with both PCa and T2DM, as coexistence of PCa and its subsequent treatments could potentially worsen T2DM control.

show abstract

Section: Discussionmentioning

confidence: 88%

Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The study of cancer in the setting of DM is burgeoning, and there is an urgent need for further data on patient-centered outcomes. We previously investigated the effects of several different solid tumors (breast, prostate and lung) and DM on patient outcomes and care [ 13–15 ]. In all of these studies, DM did not affect cancer short-term survival, and each cancer did not affect glycemic control in patients with DM.…”

Section: Discussionmentioning

confidence: 99%

Survival and Glycemic Control Outcomes Among Patients with Coexisting Pancreatic Cancer and Diabetes Mellitus

et al. 2018

View full text Add to dashboard Cite

Aim:We aimed to determine the effect of diabetes mellitus (DM) on survival in pancreatic cancer and effects of pancreatic cancer on glycemic control in DM.Materials & methods:Patients with pancreatic cancer from 2007 to 2015, with and without DM, were matched 1:1. We compared characteristics between the groups and assessed 2-year survival with Kaplan–Meier analysis.Results:In patients with DM, hemoglobin A1c decreased significantly over time (p = 0.01). In survival analysis, 2-year overall survival estimates were 15% (95% CI: 8–24%) for DM patients versus 26% (95% CI: 17–36%) for non-DM patients (p = 0.55). The hazard ratio for matched pairs was 1.15 (95% CI: 0.75–1.77; p = 0.51).Conclusion:DM did not decrease survival in pancreatic cancer. Pancreatic cancer did not affect glycemic control.

show abstract

“…Little is known about how DM and solid-organ cancers interact to influence each other's outcomes on an individual level. We previously investigated effects of breast cancer and DM on patient outcomes and care [ 17 ], as well as these same effects of prostate cancer and DM [ 19 ]. In both analyses, DM did not impact survival in breast cancer or prostate cancer, and each cancer did not affect short-term (i.e., 1 year) glycemic control among patients with DM.…”

Section: Discussionmentioning

confidence: 99%

Patient Outcomes from Lung Cancer and Diabetes Mellitus: A Matched Case–Control Study

et al. 2017

View full text Add to dashboard Cite

Aim:This case–control study examined the impact of diabetes mellitus (DM) on survival in lung cancer patients and lung cancer on glycemic control in DM.Materials & methods:Patients with a new lung cancer diagnosis and DM (n = 124) were matched to 124 lung cancer patients without DM. Laboratory results and DM and cancer therapies were obtained from electronic records.Results:Five-year overall survival for lung cancer patients with and without DM was 20 versus 29% (p = .12). Glycemic control among DM patients did not change significantly with time.Conclusion:DM does not cause adverse impact on lung cancer survival. Lung cancer does not affect glycemic control.

show abstract

Co-Existing Prostate Cancer and Diabetes Mellitus: Implications for Patient Outcomes and Care

Cited by 22 publications

References 11 publications

Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study

Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study

Survival and Glycemic Control Outcomes Among Patients with Coexisting Pancreatic Cancer and Diabetes Mellitus

Patient Outcomes from Lung Cancer and Diabetes Mellitus: A Matched Case–Control Study

Contact Info

Product

Resources

About